financetom
Business
financetom
/
Business
/
Bristol-Myers Squibb Unusual Options Activity For July 15
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bristol-Myers Squibb Unusual Options Activity For July 15
Jul 15, 2024 12:05 PM

Financial giants have made a conspicuous bearish move on Bristol-Myers Squibb ( BMY ). Our analysis of options history for Bristol-Myers Squibb ( BMY ) revealed 10 unusual trades.

Delving into the details, we found 30% of traders were bullish, while 70% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $136,531, and 7 were calls, valued at $647,002.

Predicted Price Range

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $25.0 to $50.0 for Bristol-Myers Squibb ( BMY ) during the past quarter.

Analyzing Volume & Open Interest

Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Bristol-Myers Squibb's ( BMY ) options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Bristol-Myers Squibb's ( BMY ) substantial trades, within a strike price spectrum from $25.0 to $50.0 over the preceding 30 days.

Bristol-Myers Squibb Option Volume And Open Interest Over Last 30 Days

Noteworthy Options Activity:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
BMY CALL SWEEP BULLISH 01/16/26 $15.75 $15.6 $15.7 $25.00 $196.2K 2.9K 219
BMY CALL TRADE BEARISH 01/16/26 $15.9 $15.75 $15.75 $25.00 $155.9K 2.9K 113
BMY CALL SWEEP BULLISH 01/16/26 $16.0 $15.6 $16.0 $25.00 $87.7K 2.9K 30
BMY CALL SWEEP BEARISH 08/15/25 $1.64 $1.54 $1.64 $50.00 $86.6K 1.6K 0
BMY PUT SWEEP BEARISH 12/20/24 $8.35 $8.25 $8.35 $48.00 $49.2K 613 0

About Bristol-Myers Squibb

Bristol-Myers Squibb ( BMY ) discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

Following our analysis of the options activities associated with Bristol-Myers Squibb ( BMY ), we pivot to a closer look at the company's own performance.

Present Market Standing of Bristol-Myers Squibb

With a trading volume of 9,670,839, the price of BMY is down by -1.12%, reaching $40.01.

Current RSI values indicate that the stock is is currently neutral between overbought and oversold.

Next earnings report is scheduled for 11 days from now.

What Analysts Are Saying About Bristol-Myers Squibb

A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $41.0.

An analyst from Barclays has decided to maintain their Equal-Weight rating on Bristol-Myers Squibb ( BMY ), which currently sits at a price target of $41.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Bristol-Myers Squibb ( BMY ) with Benzinga Pro for real-time alerts.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
WH Group get shareholders' nod to spin off Smithfield Foods
WH Group get shareholders' nod to spin off Smithfield Foods
Dec 6, 2024
Dec 6 (Reuters) - Hong Kong-based WH Group ( WHGRF ), the world's largest pork producer, said on Friday its shareholders approved the spin off of its U.S. subsidiary, Smithfield Foods, into a listed company in the United States. ...
CyberArk Software Launches Secondary Public Offering
CyberArk Software Launches Secondary Public Offering
Dec 6, 2024
06:30 AM EST, 12/06/2024 (MT Newswires) -- CyberArk Software ( CYBR ) said Thursday it launched an underwritten secondary public offering by Triton Seller of about 1.1 million ordinary shares. The company said it will not receive any proceeds from the sale of the shares offered by the selling shareholders. ...
BRP Normalized Net Income Falls, Beats Estimates
BRP Normalized Net Income Falls, Beats Estimates
Dec 6, 2024
06:27 AM EST, 12/06/2024 (MT Newswires) -- BRP (DOOO) on Friday reported a decrease in third-quarter normalized net income on lower North American retail sales amid softer demand. Third-quarter normalized net income fell to $85.2 million, or $1.16 per share, compared with $252.1 million, or $3.24 per share. The results beat the FactSet consensus earnings per share estimate of $0.67....
BRP's Fiscal Q3 Normalized Earnings, Revenue Fall; Fiscal 2025 Outlook Revised
BRP's Fiscal Q3 Normalized Earnings, Revenue Fall; Fiscal 2025 Outlook Revised
Dec 6, 2024
06:27 AM EST, 12/06/2024 (MT Newswires) -- BRP (DOOO) reported fiscal Q3 normalized earnings Friday of 1.16 Canadian dollars ($0.83) per diluted share, down from CA$3.24 a year earlier. Analysts surveyed by FactSet expected CA$0.68. Revenue for the quarter ended Oct. 31 was CA$1.96 billion, compared with CA$2.37 billion a year earlier. Analysts surveyed by FactSet expected CA$1.9 billion. The...
Copyright 2023-2026 - www.financetom.com All Rights Reserved